Resolving Eosinophil And Inflammatory Heterogeneity In Chronic Allergic Airway Disease For Safer, Effective And Lasting Precision Therapies
Funder
National Health and Medical Research Council
Funding Amount
$1,166,165.00
Summary
Many patients with upper airway inflammation and asthma have poorly controlled disease and are in need of new effective therapies. We have discovered new cell subsets in the airways of these patients. We will use cutting edge single cell and spatial analysis of human tissues to define human allergic disease and inflammatory cells at unprecedented resolution. This will identify new targets for treatment and match patients with effective therapies to facilitate precision therapy.
The Cellular Basis Of Synaptic Integration And Modulation In Human Pyramidal Neurons
Funder
National Health and Medical Research Council
Funding Amount
$917,355.00
Summary
Little is known about how human neurons integrate information, and how this process is altered during neuromodulation and disease. This project will address this fundamental gap in knowledge and will for the first time directly examine the neuromodulation of human neurons, and how this important process is altered in brain cancer. Our team of researchers and surgeons in Melbourne and Berlin will be able to provide valuable, and otherwise unattainable, information about the human brain.
Targeting A Bacterial Glyco-Achilles Heel To Make New Vaccines For Haemophilus Influenzae And Neisseria Gonorrhoeae.
Funder
National Health and Medical Research Council
Funding Amount
$526,950.00
Summary
The bacteria that cause gonorrhoea (N. gonorrhoeae), middle ear infections and exacerbations of chronic obstructive lung disease (H. influenzae) have become multi-drug resistant. These diseases are a major health and economic burden. In the absence of new drugs, a vaccine to prevent these diseases has emerged as a major unmet need in human health. In this grant, we will develop a new vaccine that targets a bacterial-specific sugar that we have discovered is the Achilles heel of these bacteria.
Virulence Associated Small RNAs In Acinetobacter Baumannii
Funder
National Health and Medical Research Council
Funding Amount
$964,148.00
Summary
This proposal aims to understand how a superbug that causes severe infections in hospitalised patients worldwide and is known to be resistant to almost all available antibiotics, causes disease. We then plan on using this information to guide the development of a new type of therapy to treat this severe infection.
Silencing Pulmonary Nociceptors To Treat Severe Respiratory Viral Infections
Funder
National Health and Medical Research Council
Funding Amount
$534,173.00
Summary
The lungs receive a rich supply of nerve fibres, many of which play an important role in helping defend against pathogens, including viruses. When viral infections become severe, too much inflammation occurs in the lungs and this creates a serious and difficult to treat clinical problem. Hundreds of thousands of people each year die from the complications of severe lung infections. We are investigating a potential new therapy that targets the lung nerves and relieves excessive inflammation.
First-in-human Evaluation Of A Novel Immunobiotic To Prevent Respiratory Infection
Funder
National Health and Medical Research Council
Funding Amount
$1,180,080.00
Summary
Respiratory infections are a leading cause of death and illness throughout the world. We have discovered a 'friendly' bacteria that can be applied up the nose to prevent ear infections and the 'flu in mice. We will now test this novel therapy in humans to check it is safe and that it stimulates the human immune system in the same way that it does in mice. This will provide essential information to conduct clinical trials, with the aim to produce a medicine that prevents respiratory infections.
Vascular Changes Are A Key Contributor To And Novel Drug Target For Interferon-alpha Induced Neurological Disease
Funder
National Health and Medical Research Council
Funding Amount
$1,245,401.00
Summary
Type I interferons (IFN-Is) contribute to wide range of neurological diseases including ageing and neurodegeneration. At its extreme IFN-I-mediated neurodegeneration is known as 'interferonopathy'. The mechanisms of how IFN-Is drive disease are unclear, making causal treatment difficult. We have recently uncovered ground-breaking evidence that abnormal blood vessels are a key contributor to the disease. Here, we will investigate novel treatment targets for patients with interferonopathies.